New treatment options for patients with metastatic prostate cancer

被引：0

作者：

Snoeks, L. L. ^{[1
]}

Ogilvie, A. C. ^{[1
]}

van Haarst, E. P. ^{[2
]}

Siegert, C. E. H. ^{[1
]}

机构：

[1] Sint Lucas Andreas Hosp, Dept Internal Med, Amsterdam, Netherlands

[2] Sint Lucas Andreas Hosp, Dept Urol, Amsterdam, Netherlands

来源：

NETHERLANDS JOURNAL OF MEDICINE | 2013年 / 71卷 / 06期

关键词：

Abiraterone; cabazitaxel; CRPC; enzalutamide; prostate cancer; INCREASED SURVIVAL; ABIRATERONE; MITOXANTRONE; PREDNISONE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer is one of the most common cancers in men. When metastasised (40% of patients), classic anti-androgen therapy is the first-line treatment. Usually, this treatment becomes ineffective when castration-resistant prostate cancer (CRPC) develops. Thus far, docetaxel was the only chemotherapeutic option that has shown to be able to extend overall survival and improve quality of life in these patients. Recently, cabazitaxel and abiraterone have shown significant survival benefits for patients progressive on or after docetaxel treatment, as did enzalutamide and radium-223. In North America, immune therapy (sipuleucel-T) became available for a subgroup of CRPC patients. These new treatment options will change the treatment paradigm of patients with metastatic castration-resistant prostate cancer. A multidisciplinary approach by both medical oncologists and urologists seems mandatory.

引用

页码：290 / 294

页数：5

共 18 条

[1]

[Anonymous], 2007, CBO RICHTL PROST DIA

[2]

Bergman AM, 2011, THERAPIE ACTUEEL, V4, P160

[3] Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989-2006 [J].

Cremers, R. G. H. M. ;

Karim-Kos, H. E. ;

Houterman, S. ;

Verhoeven, R. H. A. ;

Schroder, F. H. ;

van der Kwast, T. H. ;

Kil, P. J. M. ;

Coebergh, J. W. W. ;

Kiemeney, L. A. L. M. .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) :2077-2087

[4] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer [J].

Dayyani, Farshid ;

Gallick, Gary E. ;

Logothetis, Christopher J. ;

Corn, Paul G. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1665-1675

[5] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[6] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[7] Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [J].

Fizazi, Karim ;

Scher, Howard I. ;

Molina, Arturo ;

Logothetis, Christopher J. ;

Chi, Kim N. ;

Jones, Robert J. ;

Staffurth, John N. ;

North, Scott ;

Vogelzang, Nicholas J. ;

Saad, Fred ;

Mainwaring, Paul ;

Harland, Stephen ;

Goodman, Oscar B., Jr. ;

Sternberg, Cora N. ;

Li, Jin Hui ;

Kheoh, Thian ;

Haqq, Christopher M. ;

de Bono, Johann S. .

LANCET ONCOLOGY, 2012, 13 (10) :983-992

[8] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[9] Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer [J].

Knudsen, Karen E. ;

Scher, Howard I. .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4792-4798

[10]

Mason M, 2010, ANN ONCOL S8, V21

← 1 2 →